Navigation Links
Watson Launches Generic FEMCON(R) Fe
Date:9/26/2011

PARSIPPANY, N.J., Sept. 26, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has launched Norethindrone and Ethinyl Estradiol Tablets (Chewable), 0.4 mg/0.035 mg and Ferrous Fumarate Tablets (Chewable), 75 mg, a generic version of Warner Chilcott's FEMCON(R) Fe. Watson began shipping the product today. FEMCON(R) Fe is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.

For the most recent twelve months ending July 31, 2011, FEMCON(R) Fe had sales of approximately $35 million, according to IMS Health data.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's quarterly report on form 10-Q for the quarter ended June 30, 2011 and Watson's annual report on Form 10-K for the year ended December 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

FEMCON(R) Fe is a registered trademark of Warner Chilcott Company, Inc.

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)CONTACTS:Investors:Patty Eisenhaur(862) 261-8141Media:Charlie Mayr(862) 261-8030
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson to Host Conference Call and Webcast to Discuss Third Quarter 2011 Earnings
2. Watson to Present at the Jefferies 2011 Global Healthcare Conference
3. Watson Confirms Amphastar Patent Lawsuit
4. Watson Pharmaceuticals Announces Approval of Amphastars Generic LOVENOX(R)
5. Watson to Present at the 2011 Bank of America Merrill Lynch Global Healthcare Conference
6. Watson to Present at the 2011 Morgan Stanley Global Healthcare Conference
7. Watsons Anda Distribution to Build 234,000 sq ft Pharmaceutical Warehouse and Distribution Facility in Olive Branch, DeSoto County, MS
8. Watson Enters into Agreement to Acquire Products Related to Perrigos Acquisition of Paddock Laboratories
9. Watson Second Quarter 2011 Net Revenue Exceeds $1 Billion; Non-GAAP EPS of $1.01
10. Watson Confirms JALYN™ Patent Challenge
11. Watson Confirms Favorable Appeals Court Decision in Mucinex(R) Patent Suit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 23, 2017  Galmed Pharmaceuticals Ltd. (Nasdaq: ... clinical-stage biopharmaceutical company focused on the development of ... nonalcoholic steatohepatitis, or NASH, and other liver diseases, ... twelve months ended December 31, 2016, and announced new ... demonstrating Aramchol™,s potential direct effect on liver fibrosis. ...
(Date:3/23/2017)... , March 23, 2017 AbbVie, a global ... Award-winning choreographer Julianne Hough is helping to ... in the Know about ME in EndoMEtriosis . " ... inspiring women to learn about and understand endometriosis, a ... and to address their symptoms with a healthcare ...
(Date:3/23/2017)... Calif. , March 23, 2017   Casetabs ... of a native mobile app for the iPhone. With ... for surgery coordination and communication for physician offices, ambulatory ... native mobile app offers iPhone users even faster, more ... is making it even easier to connect care teams ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... Inflow IQ & Inflownomics of Raleigh, NC introduce ... a solid foundation. As experts in dangerous situations the Inflow IQ team can ... Inflownomics deliver ripe, fresh, clean & refreshing knowledge systems that enhance life. ...
(Date:3/23/2017)... ... March 23, 2017 , ... The founders of Dr. Wang ... winners of American Dreams & Good Housekeeping Seal Initiative, a nationwide search for ... Good Housekeeping. , Steven Wang, MD ., a renowned dermatologist and medical ...
(Date:3/23/2017)... ... March 23, 2017 , ... GeBBS Healthcare Solutions unveils the ... 21st annual Compliance Institute on March 26-28 in National Harbor, Maryland. ... chart types with a comprehensive set of features including built-in workflow, interactive audit ...
(Date:3/23/2017)... ... March 23, 2017 , ... “My Journey Through Heaven”: ... with an infinitely more profound faith of God’s promise of Heaven for His people. ... who spends each day with his wife, three children and six grandchildren living and ...
(Date:3/23/2017)... , ... March 23, 2017 , ... “More Corruption”: a simple and strong explanation ... is one of the rulers of Heaven was asked by God to write a book ... discrimination against me just because I kept my commitment to the Lord God. They have ...
Breaking Medicine News(10 mins):